Evaluation of Preeclampsia Results after Use of Metformin in Gestation: Systematic Review and Meta-analysis

Avaliação dos resultados da pré-eclâmpsia após o uso da metformina na gestação: revisão sistemática e metanálise

Iramar Baptistella do Nascimento1  Guilherme Dienstmann1  Matheus Leite Ramos de Souza1  Raquel Fleig1  Carla Beatriz Pimentel Cesar Hoffmann1  Jean Carl Silva1

1 Department of Postgraduate in Health and Environment, Universidade da Região de Joinville, Joinville, Brazil

Address for correspondence  Iramar Baptistella do Nascimento, PhD, Departamento de Pós-Graduação em Saúde e Meio Ambiente, Universidade da Região de Joinville, Rua Paulo Malschitzki, 10, 89219-710, Joinville, SC, Brazil (e-mail: iramar.nascimento@udesc.br).

Abstract

Objective  Does the use of metformin have an influence on the outcomes of preeclampsia (PE)?

Sources of Data  The descriptors pregnancy, metformin, treatment, and preeclampsia associated with the Boolean operators AND and OR were found in the MEDLINE, LILACS, Embase and Cochrane databases. A flowchart with exclusion criteria and inclusion strategy using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol, and eligibility criteria was used. Data were extracted regarding the type of study, the applied dosage, treatment time, segment, bias risks, and the Patient, Intervention, Comparison and Outcome (PICO) strategy to identify the quality of the study.

Selection of Studies  Total number of journals in the initial search (n = 824); exclusions from repeated articles on different search engines (n = 253); exclusions after reading the titles, when the title had no correlations with the proposed theme (n = 164); exclusions due to incompatibility with the criteria established in the methodological analysis (n = 185), exclusion of articles with lower correlation with the objective of the present study (n = 187); and final bibliographic selection (n = 35).

Data Collection  At first, a systematic review of the literature was performed. Subsequently, from the main selection, randomized and non-randomized trials with metformin that presented their results in absolute and relative numbers of PE outcomes were selected. The variables were treated statistically in the meta-analysis with the Review Manager software (RevMan), version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration. Denmark in the Hovedistaden region.

Synthesis of Data  The study showed that metformin presented greater preventive effects for pregnancy-induced hypertension and was less effective for PE.
Conclusion Metformin may gain place in preventive treatments for PE, once the dosages, the gestational age, and treatment time are particularly evaluated. A methodological strategy with an improved perspective of innovative and/or carefully progressive dosages during pregnancy to avoid side effects and the possibility of maternal-fetal risks is suggested.

Resumo

Objetivo O uso de metformina tem influência nos resultados da pré-eclâmpsia (PE)?

Fontes de Dados Os descritores gravidez, metformina, tratamento e pré-eclâmpsia associados aos operadores booleanos AND e OR foram encontrados nas bases de dados MEDLINE, LILACS, Embase e Cochrane. Foi utilizado um fluxograma com critérios de exclusão e estratégia de inclusão, utilizando o protocolo Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA e critérios de elegibilidade. Os dados foram extraídos quanto ao tipo de estudo, dosagem aplicada, duração do tratamento, segmento, riscos de viés e estratégia Patient, Intervention, Comparison and Outcome (PICO) para identificar a qualidade do estudo.

Seleção de Estudos Número total de periódicos na busca inicialmente realizada (n = 824); exclusões de artigos repetidos nos diferentes sites de busca (n = 253); exclusões após a leitura dos títulos, quando o título não apresentava correlações com o tema proposto (n = 164); exclusões por incompatibilidade com os critérios estabelecidos na análise metodológica (n = 185), exclusões de artigos com menor correlação com o objetivo do presente estudo (n = 187); e seleção bibliográfica final (n = 35).

Coleta de Dados Inicialmente, foi realizada uma revisão sistemática da literatura. Posteriormente, a partir da seleção principal, foram selecionados estudos randomizados e não randomizados com metformina, os quais apresentaram em seus resultados números absolutos e relativos de desfechos de PE. As variáveis foram tratadas estatisticamente na metaanálise por meio do Review Manager software (RevMan), version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, Denmark in the Hovedistaden region.

Síntese dos Dados O estudo demonstrou que a metformina apresenta maiores efeitos preventivos para a hipertensão induzida pela gravidez e é menos eficaz para a PE.

Conclusão A metformina pode conquistar seu espaço nos tratamentos preventivos da PE, uma vez que as dosagens, a idade gestacional e o tempo de tratamento são particularmente avaliados. Sugere-se uma estratégia metodológica com uma perspectiva aprimorada de doses inovadoras e/ou cuidadosamente progressivas durante a gravidez, a fim de evitar efeitos colaterais e a possibilidade de riscos materno-fetais.

Introduction

Specific Hypertensive Gestation Syndromes (SHGS) have become the object of great apprehension, both worldwide and in Brazil.\textsuperscript{1} According to the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy (2000), these syndromes are classified as: chronic hypertension, pregnancy-induced hypertension (PIH), preeclampsia (PE), and eclampsia.\textsuperscript{2}

Regarding PE, among the possible multifactorial causes that ratify its incidence are gestational diabetes mellitus (GDM) and weight gain above normal levels by pregnant women.\textsuperscript{3,4} The scientific literature points to the close relationship between dyslipidemia, hyperglycemia and maternal obesity with the outcomes of PE.\textsuperscript{3,5} Since it has been one of the main causes of gestational deaths in Brazil.\textsuperscript{1}

A recent study using metformin hydrochloride demonstrated satisfactory results in pregnancy.\textsuperscript{3} In addition to its pharmacokinetic action, which decreases gluconeogenesis in the liver, the drug has been successfully used in the treatment of polycystic ovary syndrome (PCOS).\textsuperscript{6,7}

In contrast, the drug presented a risk of intolerance. However, 20 randomized trials did not report serious side effects, and the impact of therapies and outcomes of the action of metformine during pregnancy is relatively recent.\textsuperscript{8}

Recent studies suggest a possible decrease in specific hypertensive disease of pregnancy (SHDP), mainly a reduction in the incidence of PIH.\textsuperscript{9,10} This fact is consistent because of the pharmacodynamics action of metformin on vascular endothelial growth factor (VEGF) related receptors and its effect of inducing a decrease in the production of angiogenic factors, improving vascular dysfunction.\textsuperscript{3,11,12}
Therefore, the hypothesis was to search, through a systematic review and meta-analysis, the use of metformin in pregnancy and the consequent investigation of the statistical parameters on the outcomes of PE in the scientific literature. In this way, the present study aimed to evaluate the results of PE after the use of metformin in different treatments during pregnancy, that is, if the use of metformin has an influence on the outcomes of PE.

**Methods**

A systematic review of the literature and a meta-analysis were performed between January 1, 2000, and March 30, 2018. A protocol was developed involving an evaluation report with different scientific studies. In this protocol, the 27 established items of the the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol checklist were used. Since the present study was a systematic review and a meta-analysis, the approval of an ethics committee was not required.

**Eligibility Criteria**

The preference was for the researches with results of PE as primary outcome, and PIH was verified in the analysis to better understand the preventive action of metformine. Randomized clinical trials with the use of metformin hydrochloride in gestation were prioritized. However, other non-randomized studies with relevance to our purposes were selected if there was a higher correlation with the research objective. Among these, there were: systematic reviews and meta-analyses; prospective cohort studies; retrospective surveys; control cases; cross-sectional studies; laboratory clinical studies; epidemiological research; studies about methods used and statistical programs.

The search for books and websites was designed by means of a selection criteria. The selected books and websites had to clarify norms, techniques and strategies to avoid bias. Consequently, a literary research was carried out in different scientiﬁc databases. The descriptors used with the characteristics of the populations in the different articles were included. The search for statistical data with metformin use in reducing PE was performed. In literature review studies, the search for compatible clinical trials with the meta-analysis was done. In literature review studies, the search for statistical data with metformin use in reducing PE risks was assessed. In the other studies, the samples and the methodological quality evaluation in the different studies were analyzed. The investigators independently assessed the bias risk. Three authors did the search and, if there was doubt between two or more researchers, a fourth person of the group would have to do the analysis with the methodological parameters and pre-established strategies.

**Assessment of bias and methodological quality in the different studies**

Attempts were made to identify the biases in selection and gauging. In this way, the following strategies were used: the research group analyzed whether a clinical trial research was in line with the pre-established objectives, that is, how the design, data collection and analysis were conducted with possible outcomes. We have tried to observe the bias of the collections by examining their data analysis and the possible impartiality in the criterion of choice, by the different scholars, in the diverse scientiﬁc researches. Consequently, the techniques used with the characteristics of the populations in the different articles were used. Attempts were made to find the confounding effects on the outcomes obtained. The evaluations of gestational age (GA) of the research, dosages used, design and comparison of the clinical characteristics of the patients included in each study, and period of administration of metformin in the intervention groups were done in a similar way. Consequently, the search for the recent statistical values of greater impact in a comparative dynamic with other previous results was performed.

In the cohort studies, the different treatments with metformin were observed regarding the reduction in the risk of PE. Therefore, they were evaluated as follows: if the sample was adequate, if the similarity between the groups under observation existed, if they presented risks for the outcome of PE, and if the information regarding the outcomes was obtained in a similar way. Then, the similarity in both groups.

In other studies, we observed different directions that allowed complementary information and/or enriching the present research. Therefore, the same investigative properties
were maintained, evaluating the particularities, reliability and validity of the data, both in the quality of the evidence in the studies selected in the systematic reviews and in the veracity of the results. As a support, the authors used the manual for systematic reviews of interventions.15

The main outcomes assessed were: PE outcomes in metformin versus placebo therapies in non-diabetic obese pregnant women; PE outcomes in metformin versus placebo therapies in pregnant women with PCOS; and PE outcomes in metformin versus insulin therapies in pregnant women with GDM.

The secondary outcomes assessed were: PIH outcomes in metformin versus placebo therapies in non-diabetic obese pregnant women; PIH outcomes in metformin versus placebo therapies in pregnant women with PCOS; and PIH outcomes in metformin versus insulin therapies in pregnant women with GDM.

At first, a systematic review of the literature was performed. Consecutively, from the main selection, randomized and non-randomized trials with metformin, that presented their results in absolute and relative numbers of PE outcomes were selected.

The variables were treated statistically by means of the Review Manager software (RevMan), (version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration. Denmark in the Hovedistaden region) in the meta-analysis. We have evaluated the primary outcomes in a fixed model using the inverse variance (IV) method. Adverse events were pooled with risk ratios (RR) using the
Mantel-Haenszel method. The existence or not of heterogeneity was evaluated by the chi-squared ($X^2$) test and measured by the I-squared ($I^2$) test. The heterogeneity was considered significant when the $X^2$ test presented $p < 0.1$ and measures of consistency, that is, high inconsistency was considered when $I^2 > 50\%$.16

When chi-squared ($X^2$) $p > 0.1$, it means that there was homogeneity (non-heterogenous result), that is, the heterogeneity was not significant. Therefore, $p \geq 0.1$ means that the following differences did not occur: clinical, methodological and statistical in the studies selected for meta-analysis. When values of $p < 0.1$, it means that the heterogeneity was considered significant, that is, there were diversities between the selected studies.

Risk ratios (RR) ($P < 0.01$) The meta-analysis presented a statistically significant difference indicating a percentage of relative risk with the metformin use. When ($p > 0.01$) there was no statistically significant difference.

Results

From the initial selection of publications added to the bases chosen and the proposed criteria, a total of 35 articles was obtained. The journals demonstrated search techniques and strategies, laboratory clinical analysis of the pharmacodynamics action of metformin, possible doses already applied, GA at the initiation of treatment, metformin therapies compared with placebo groups, research comparing the results of the drug with insulin during gestation, and other relevant outcomes.

Among the investigations, 8 (22.85%) were randomized clinical trials, 3 (8.57%) non-randomized clinical trials, 6 (17.14%) systematic reviews with a meta-analysis, 5 (14.28%) systematic reviews, 3 (8.57%) methodological studies and analysis techniques, 2 (5.71%) prospective cohort, 2 (5.71%) retrospective cohorts, 2 (5.71%) case controls, 2 (5.71%) epidemiological researches, and 2 (5.71%) clinical study laboratory tests (►Table 1).

Risk Ratio in Maternal Outcomes for pregnancy-induced hypertension and preeclampsia

The RRs grouped in the studies were as follows: randomized studies of obese pregnant women for PIH did not report significant values of risk reduction with metformin (RR = 1.24; 95% CI: 0.76–2.02; $p = 0.379$), while the researches presented homogeneity ($p = 0.376$) ($p > 0.01$) and low inconsistency ($I^2 = 0\%$), as shown in ►Fig. 2A. For the randomized studies of obese women with PE outcomes, the risk was shown to be decreased in the occurrence of disease (RR = 0.51; 95% CI: 0.26–0.98; $p = 0.042$), considering that the treatments indicated a reduction of 49% in the risk of incidence. However, they showed heterogeneity in the studies ($p = 0.007$) and high inconsistency ($I^2 = 86\%$), as shown in ►Fig. 2B.

The non-randomized investigations of pregnant women with PCOS for PIH (RR = 0.37; 95% CI: 0.25–0.57; $p = 0.000$) ($p < 0.01$), the parameters were directed toward risk reduction for PIH with a possible 63% reduction with drug use. The researches presented homogeneity ($p = 0.995$) ($p \geq 0.1$) and low inconsistency ($I^2 = 0\%$) (►Fig. 3A), and for those

Table 1 Selected scientific studies for meta-analysis using metformin

<table>
<thead>
<tr>
<th>Study and year of publication</th>
<th>Type of study</th>
<th>Dosage</th>
<th>Population</th>
<th>Segment</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiswick et al. (2015)17</td>
<td>Randomized clinical trial</td>
<td>500 mg/d to 2500 mg/d</td>
<td>Pregnant women with obese</td>
<td>5 to 6 months</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Syngelaki et al. (2016)11</td>
<td>Randomized clinical trial</td>
<td>500 mg/d to 3000 mg/d</td>
<td>Pregnant women with obese</td>
<td>5 to 6 months</td>
<td>USA and United Kingdom</td>
</tr>
<tr>
<td>Nawaz et al. (2010)18</td>
<td>Control case</td>
<td>1500 mg/d</td>
<td>Pregnant women with PCOS</td>
<td>5 to 6 months</td>
<td>Pakistan</td>
</tr>
<tr>
<td>El Hameed et al. (2011)19</td>
<td>Non-randomized clinical trial</td>
<td>2500 mg/d</td>
<td>Pregnant women with PCOS</td>
<td>2 to 3 months</td>
<td>Egypt</td>
</tr>
<tr>
<td>Khattab et al. (2011)10</td>
<td>Prospective cohort</td>
<td>1000 mg/d to 1.500 mg/d</td>
<td>Pregnant women with PCOS</td>
<td>6 to 8 months</td>
<td>Egypt</td>
</tr>
<tr>
<td>Vanky et al. (2004)20</td>
<td>Randomized clinical trial</td>
<td>1700 mg/d</td>
<td>Pregnant women with PCOS</td>
<td>1 to 5 months</td>
<td>Norway</td>
</tr>
<tr>
<td>Vanky et al. (2010)13</td>
<td>Randomized clinical trial</td>
<td>2000 mg/d</td>
<td>Pregnant women with PCOS</td>
<td>5 to 6 months</td>
<td>Norway</td>
</tr>
<tr>
<td>Rowan et al. (2008)12</td>
<td>Randomized clinical trial</td>
<td>2500 mg/d</td>
<td>Pregnant women with DMG</td>
<td>4 to 5 months</td>
<td>Norway, New Zealand, and Australia</td>
</tr>
<tr>
<td>Tertti et al. (2013)23</td>
<td>Randomized clinical trial</td>
<td>500 mg/d to 1.000 mg/d</td>
<td>Pregnant women with DMG</td>
<td>6 to 7 months</td>
<td>Finland</td>
</tr>
<tr>
<td>Niromanesh et al. (2012)24</td>
<td>Randomized clinical trial</td>
<td>500 mg/d to 2.500 mg/d</td>
<td>Pregnant women with DMG</td>
<td>4 to 5 months</td>
<td>Iran</td>
</tr>
</tbody>
</table>

Abbreviations: DMG, gestational diabetes mellitus; PCOS, polycystic ovarian syndrome.
randomized with PCOS for PE (RR = 1.96, 95% CI: 0.81 – 4.77; p = 0.137) (p > 0.01), the result did not express risk reduction for PIH, indicating homogeneity in the surveys (p = 0.130) (p > 0.01) and low inconsistency (I² = 0%), according to – Fig. 3B.

The randomized studies of diabetic pregnant women for PIH (RR = 0.53; 95% CI: 0.31 – 0.90; p = 0.018) (p > 0.01), indicated a 47% risk reduction with metformin compared with insulin, showing homogeneity among the surveys evaluated (p = 0.709) (p > 0.01), and with low inconsistency (I² = 0%); – Fig. 4A. The randomized trials of diabetic pregnant women for PE (RR = 0.70; 95% CI: 0.45 – 1.10; p = 0.124) (p > 0.01) showed no significant values, with homogeneity (p = 0.731) (p > 0.1) and low inconsistency (I² = 0%), as shown in – Fig. 4B.

For all events, the pooled studies were homogeneous (X²; p > 0.01), except for RR of randomized studies of obese pregnant women for PE outcomes (p = 0.007; I² = 86%), as shown in – Figs. 2, 3 and 4.

**Discussion**

The present study provided a brief overview of the use of metformin for the prevention of PE in research with obese
patients, PCOS and GDM. The results indicated that metformin reduced PE in treatments with obese pregnant women \((p < 0.01)\), but not in pregnant women with PCOS and GDM \((p > 0.01)\). In PIH, the drug showed significant values for both PCOS patients and pregnant women with GDM.

Since 2009, researchers have pointed out the equivalence of metformin with insulin or its use as possible alternative treatment for GDM. However, due to its ease of passage through the placenta, it should be used with determination and caution.\(^{23,25}\) Therefore, the conceivable use of metformin proposes a coadjuvant alternative in pregnancy, since as an insulin-sensitizing agent, it has shown a reduction of GDM and maternal obesity, and, in the scientific bibliography, these intercurrences demonstrated greater associations with SHGS.\(^{5,10,11,26}\)

Regarding the prevention of PIH and PE, metformin suggests a greater attenuation of angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and endoglin (ENG), acting on soluble vascular endothelial growth factor receptor-1 and soluble ENG receptors, with improvements in vascular dysfunctions.\(^3,12\) Thus, in view of the drug pharmacokinetics and pharmacodynamics action, it has been used, among others, in comparisons with placebo groups with non-diabetic pregnant women, with pregnant women with PCOS, and compared with insulin in the treatment of GDM.\(^{17,21,22}\)

**Preeclampsia Outcomes in Metformin versus Placebo Therapies in Non-diabetic Obese Pregnant Women**

In an observational cohort study, researchers identified groups with higher body mass index (BMI) (overweight and obesity) are more likely to have complications and major intercurrences related to SHGS.\(^5\) However, although researchers have found a reduction in weight gain of the overweight pregnant mother with metformin administration, they did not confirm significance in PIH-related outcomes.\(^{11}\)

The dosage to be administered and the GA at the initiation of the treatment may be relevant in the conception of the prophylaxis of the disease. Two similar randomized trials in the current decade have shown a similarity of outcomes in PIH prophylaxis.

In the first study in 2015, the pregnant women started the administration of metformin between 12 and 16 weeks of gestation, used a dosage of 500 mg/d for 5 weeks for adaptation and, from the sixth week on, the dosage was changed to 2500 mg/d until the delivery. Since the results did not indicate significant differences for both PIH (odds ratio [OR] = 1.56; 95% CI: 0.77–3.15) and PE (OR = 2.39; CI 95%: 0.61–9.36).\(^{17}\)

In the following year, another study started the intervention at between 12 and 18 weeks of gestation with 500 mg/d per week, up to a maximum dosage of 3000 mg/d in the 5th week before the delivery. The study demonstrated for PIH (OR = 1.11; 95% CI: 0.60–2.04; \(p > 0.01\)) and, for prevention of PE, showed a difference of 3% in the metformin group compared with 11% in the placebo group (OR = 0.24; 95% CI: 0.10–0.61; \(p < 0.01\)).\(^{11}\) Our results in the meta-analysis indicated a reduction in the RR of PE (RR = 0.51; 95% CI: 0.26–0.98) in obese pregnant women who used metformin.

However, it is worth highlighting the need for more detailed observation on the dosages, since during pregnancy renal clearance becomes greater and metformin may be subsequently eliminated during the gestational period.\(^{27}\)
Outcomes of Preeclampsia in Metformin versus Placebo Therapies in Pregnant Women with Polycystic Ovary Syndrome

Polycystic ovary syndrome is an endocrine disorder of anovulatory infertility in women of reproductive age. Its prevalence depends on the criteria used, taking into account the population studied. Metformin reduces androgenic hormones and also tends to correct the insulin resistance present in practically all women with PCOS. Among other complications, DMG, PIH and PE are prevalent complications in pregnant women with PCOS.

A clinical trial with pregnant women with PCOS using 850 mg/d of metformin in the first week and 1700 mg/d for the remainder of the study period, between 5 and 12 weeks of pregnancy, showed no relevance for PE. A subsequent randomized study with similarity at the starting point for treatment, between 5 and 12 weeks of gestation, ratified non-significant values for PE \((p < 0.01)\), even at a dosage of 2000 mg/d.

In contrast, non-randomized studies showed a greater significance for PIH. Researches that used a treatment with 1500 mg/d of metformin presented a difference between the intervention groups \((16.5\% \text{ versus } 45\% \text{ [control]; } p = 0.002)\). It is worth mentioning a prospective cohort in which women were taking metformin 3 to 6 months before pregnancy and the intervention group continued to administer the drug in one dosage of 1000–2000 mg/d during gestation. The results were significant: 3% of metformin group versus 6% of control group demarcating a reduction of PIH, \((\text{OR} = 0.35; \text{95\% CI: } 0.13 \text{–} 0.94; p < 0.01)\). In contrast, authors starting with a 1000 mg/d dose, increased to 2500 mg/d and, according to the gestational BMI, did not reduce the PE values \((p = 0.58; p > 0.01)\).

**NOTE:** In this study found in the literature, there was no statistically significant value for body mass index reduction \((p > 0.01)\) showed a decrease in the risk of PIH \((\text{RR} = 0.37; 95\% \text{ CI: } 0.25 \text{–} 0.57; p = 0.000)\) in pregnant women with PCOS.

Outcomes of PE in Metformin versus Insulin Therapies in Pregnant Women with Gestational Diabetes Mellitus

Two recent meta-analyses have confirmed that the effects of metformin on GDM have demonstrated consistent and/or favorable values both for the mother and for the newborn. However, there is research that suggests more discussion about the subject. In the comparative studies using metformin versus insulin, the metformin was effective in reducing the weight of diabetic pregnant women, pointing to a higher BMI in pregnant women who administered insulin.

Study conducted in 2009 showed a strong relationship of increased BMI with chronic hypertension and PE during pregnancy. Likewise, the risks of PE in women with diabetes type I or II increased two to four times, respectively.

Randomized clinical trials have confirmed the reduction of absolute and relative values for both PIH and PE incidence, when compared metformin with insulin. A research conducted in 2008 with mothers between 20 and 33 weeks of gestation, whose hospital criteriawere to initiate insulin, usedas a starting point a dose of 500 mg metformin once or twice daily, up to 2500 mg/d. The objective was to reach adequate glycemic levels. The PIH incidence values were 3.8% of the 363 mothers who received metformin compared with 6.21% of the 370 pregnant women who received insulin. Regarding the incidence of PE, the values were 5.5% versus 7%, respectively.

Another research developed, in 2012, with 500 mg/d and, from the third day after entering in the research, increased to 1000 mg/d. Metformin group \((n = 110)\) percentages compared with control group \((n = 107)\) were: 1.8% metformin versus 3.7% control for PIH, and 4.6% metformin versus 9.4% control for PE respectively. In the same year, other investigators in a similar procedure instituted an initial dose of 500 mg twice daily and, after two weeks, increased it to 1000 mg/d, increasing until reaching the appropriate target of the glycemic standards of the pregnant women, up to 2,500 mg/d, if necessary. Metformin group \((n = 110)\) percentages compared with control group \((n = 107)\) were: 1.8% metformin versus 3.7% control for PIH, and 4.6% metformin versus 9.4% control for PE.

In the present meta-analysis, the values were significant in pregnant women with GDM only for PIH \((\text{RR} = 0.53; 95\% \text{ CI: } 0.31 \text{–} 0.90; p = 0.018)\). Thus, although metformin has not demonstrated higher prophylactic values for PE in our literary findings, this drug has been confirmed to be safe during pregnancy and has improved the acceptance of metformin by pregnant women when compared to insulin.

Conclusion

It is important to clarify that the present study presented some limitations, such as a limited number of randomized clinical trials with the use of metformin in the PE outcomes. Another factor refers to the aspects related to the lack of information about the drug to be used both on the part of the examiner and of the person examined in the different researches. This would reduce the expectations of pregnant women and/or the placebo effect, which would allow a better understanding of the therapeutic effects of the drug related to its benefits and consequences. Metformin had better effects on milder hypertensive syndromes. The drug can gain space in preventive treatments for PE, once the dosages, GA and treatment time are better evaluated in contemporary studies. Compared with insulin, metformin has gained independence and suggests an adequate methodological strategy with an improved perspective of innovative and/or carefully progressive dosages during pregnancy, to avoid side effects and possible risks.

Conflict of Interests

The authors have no conflicts of interests to declare.

Referências


